

Clinicopathological variables	N	RBX2 expression	P-value
		score (Mean ± SD)	
Age (years)			
< 60	39	7.12 ± 4.23	0.657
≥ 60	17	4.35 ± 4.11	
Tumor differentiation			
Well	11	2.79 ± 1.86	0.524
Moderate	19	4.98 ± 1.35	
Poor	26	4.32 ± 2.63	
Infiltration depth			
$T_{1} + T_{2}$	24	2.79 ± 2.74	0.004
$T_{3} + T_{4}$	32	4.31 ± 1.45	
Lymph node metastasis			
N _o	30	5.56 ± 3.17	< 0.001
N ₁₋₃	26	3.47 ± 1.73	
Distant metastasis			
Mo	29	3.84 ± 4.38	0.003
M ₁	27	4.34 ± 1.4	
TNM stage			
I	10	5.13 ± 1.72	< 0.001
II	17	5.01 ± 3.53	
III	13	3.19 ± 1.56	
IV	16	6.21 ± 4.45	

Supplementary Table 1. Association of RBX2 expression with clinic-pathological factors from patients with coloncancer



Supplementary Figure 1. A. The efficiency of RBX2 knock out plasmid transfection exhibited completely loss of RBX2 relative to parental B16F10 cells. B. Western blot analysis of RBX2 in B16F10 cells transfected with vector or RBX2.



Supplementary Figure 2. A. The effect of on everolimus on HCT116 RBX2 konoc-down cells proliferation was assayed by MTT analysis. B. Transwell invasion assay was performed to evaluate the effect of everolimus on HCT116 RBX2 knock-out cells invasion in vitro.